Invasive Aspergillosis - Pipeline Insight, 2024

This “Invasive Aspergillosis - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Invasive Aspergillosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Invasive Aspergillosis Understanding

Invasive Aspergillosis: Overview

Invasive aspergillosis is the most common mold infection in immunocompromised hosts. This infection is caused by Aspergillus, a hyaline mold that is ubiquitous. Exposure to Aspergillus conidia is frequent, but invasive disease is uncommon because of control by host immunity in nonimmunosuppressed hosts. The most common risk factors for infection include neutropenia and glucocorticoid use, but other risk factors include hematopoietic cell transplantation, solid organ transplantation (particularly lung transplantation), the use of biologic agents, pulmonary diseases, and critical illness. The most common infecting species is Aspergillus fumigatus complex, but other species complexes that are common causes of disease include A. flavus, A. terreus, and A. niger. Less common species, such as A. nidulans, A. calidoustus, A. lentulus, and many others, have been reported to cause infection in highly immunosuppressed patients. Many of these unusual or cryptic species, which are often difficult to identify, are clinically important due to varying susceptibility to antifungal agents. The effective management of invasive aspergillosis includes strategies to optimize prevention, prompt diagnosis, early antifungal treatment, and, in some cases, immunomodulation and surgery. An increasing number of cases of invasive aspergillosis have also been reported as complications of coronavirus disease 2019 infection.

Invasive Aspergillosis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Invasive Aspergillosis pipeline landscape is provided which includes the disease overview and Invasive Aspergillosis treatment guidelines. The assessment part of the report embraces, in depth Invasive Aspergillosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Invasive Aspergillosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Invasive Aspergillosis.
• In the coming years, the Invasive Aspergillosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Invasive Aspergillosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the Invasive Aspergillosis treatment market. Several potential therapies for Invasive Aspergillosis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Invasive Aspergillosis market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Invasive Aspergillosis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Invasive Aspergillosis Emerging Drugs Chapters

This segment of the Invasive Aspergillosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Invasive Aspergillosis Emerging Drugs

Olorofim: F2GOlorofim (formerly F901318) is F2G’s leading candidate from this class and has fungicidal activity against a broad range of mould infections including a variety of rare and resistant moulds that cause life-threatening infections for which current therapies have limitations or are ineffective. Olorofim has received orphan drug status from the European Medicines Agency and orphan drug status, Qualified Infectious Disease Product (QIDP) designation and Breakthrough Therapy designation from FDA.

Ibrexafungerp: SCYNEXISIbrexafungerp (formerly SCY-078) is the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. It has shown activity against Aspergillus and Candida, including against multidrug-resistant (MDR) species Candida auris as well as Pneumocystis. Ibrexafungerp combines the well-established activity of glucan synthase inhibitors with the flexibility of oral and IV formulations, offering a broad use across different settings (in-patient and out-patient).

Invasive Aspergillosis: Therapeutic Assessment

This segment of the report provides insights about the different Invasive Aspergillosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Invasive Aspergillosis

There are approx. 3+ key companies which are developing the therapies for Invasive Aspergillosis. The companies which have their Invasive Aspergillosis drug candidates in the most advanced stage, i.e. phase III include, F2G.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Invasive Aspergillosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Invasive Aspergillosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Invasive Aspergillosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Invasive Aspergillosis drugs.

Invasive Aspergillosis Report Insights

• Invasive Aspergillosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Invasive Aspergillosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Invasive Aspergillosis drugs?
• How many Invasive Aspergillosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Invasive Aspergillosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Invasive Aspergillosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Invasive Aspergillosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• F2G
• SCYNEXIS
• Pulmocide Ltd
• TFF Pharmaceuticals

Key Products

• Olorofim
• Ibrexafungerp
• PC945
• Voriconazole dry powder inhalation